A Phase II Study of Afatinib (BIBW 2992) in Patients with Adenocarcinoma of the Lung and Activating EGFR/HER1 Mutations (LUX-Lung 2)

被引：0
|
作者：
Yang, Chih-Hsin [1 ]
Shih, Jin Yuan [1 ]
Su, Wu-Chou [2 ]
Hsia, Te-Chun [3 ]
Sequist, Lecia V. [4 ]
Chang, Gee-Chen [5 ]
Calvo, Roser
Cong, Xiuyu Julie
Shahidi, Mehdi
Miller, Vincent A. [6 ]
机构：
[1] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[2] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan
[3] China Med Univ Hosp, Dept Internal Med, Taichung, Taiwan
[4] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[5] Taichung Vet Gen Hosp, Dept Internal Med, Taichung, Taiwan
[6] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S376 / S377
页数：2
相关论文
共 50 条
  • [21] LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations
    Yang, James Chih-Hsin
    Schuler, Martin H.
    Yamamoto, Nobuyuki
    O'Byrne, Kenneth John
    Hirsh, Vera
    Mok, Tony
    Geater, Sarayut Lucien
    Orlov, Sergey V.
    Tsai, Chun-Ming
    Boyer, Michael J.
    Su, Wu-Chou
    Bennouna, Jaafar
    Kato, Terufumi
    Gorbunova, Vera
    Lee, Ki Hyeong
    Shah, Riyaz N. H.
    Massey, Dan
    Lorence, Robert M.
    Shahidi, Mehdi
    Sequist, Lecia V.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] LUX-lung 3: A randomized, open-label, phase III study of afatinib vs pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations
    Schuler, Martin
    Yang, James Chih-Hsin
    Yamamoto, Nobuyuki
    O'Byrne, Ken
    Hirsh, Vera
    Mok, Tony
    Massey, Dan
    Zazulina, Victoria
    Shahidi, Mehdi
    Sequist, Lecia
    LUNG CANCER, 2012, 77 : S25 - S26
  • [23] LUX-LUNG 3: A RANDOMIZED, OPEN-LABEL, PHASE III STUDY OF AFATINIB VS. PEMETREXED AND CISPLATIN AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED ADENOCARCINOMA OF THE LUNG HARBORING EGFR ACTIVATING MUTATIONS
    O'Byrne, Ken
    Schuler, Martin
    Yamamoto, Nobuyuki
    Hirsh, Vera
    Mok, Tony
    Massey, Dan
    Zazulina, Victoria
    Shahidi, Mehdi
    Sequist, Lecia
    Yang, James
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S102 - S102
  • [24] In Vitro Study for Afatinib Efficacy in Lung Squamous Cell Carcinoma with HER2 Mutations Identified in LUX-Lung 8 Trial
    Hamada, Akira
    Suda, Kenichi
    Fujino, Toshio
    Soh, Junichi
    Mitsudomi, Tetsuya
    CANCER SCIENCE, 2021, 112 : 820 - 820
  • [25] Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials
    Passaro, Antonio
    Gori, Bruno
    de Marinis, Filippo
    JOURNAL OF THORACIC DISEASE, 2013, 5 (04) : 383 - 384
  • [26] Afatinib in Combination with Pembrolizumab in Patients with Qquamous Cell Carcinoma of the Lung: a Phase II Study (LUX-Lung IO/KEYNOTE 497)
    Levy, B.
    Bennouna, J.
    Paz-Ares, L.
    Chisamore, M. J.
    Lind, C. L.
    Sadrolhefazi, B.
    Riess, J. W.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1579 - S1579
  • [27] LUX-Lung 3: A Randomized, Open-Label, Phase III Study of Afatinib vs Pemetrexed and Cisplatin as First-Line Treatment for Patients with Advanced Adenocarcinoma of the Lung Harboring EGFR-Activating Mutations (Subgroup Analysis)
    Sequist, L.
    Schuler, M.
    Yamamoto, N.
    O'Byrne, K.
    Hirsh, V.
    Mok, T.
    Massey, D.
    Zazulina, V.
    Shahidi, M.
    Yang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S203 - S203
  • [28] SYMPTOM AND HEALTH-RELATED QUALITY OF LIFE BENEFIT OF AFATINIB (BIBW 2992) IN ADVANCED NSCLC PATIENTS PREVIOUSLY TREATED WITH ERLOTINIB OR GEFITINIB: RESULTS OF A RANDOMIZED PHASE III TRIAL (LUX-LUNG 1)
    Hirsh, Vera
    Cadranel, Jacques
    Cong, Julie
    Fairclough, Diane
    Finnern, Henrik
    Lorence, Robert
    Miller, Vincent A.
    Palmer, Mike
    Yang, James Chih-Hsin
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S324 - S325
  • [29] Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials
    Wu, Yi-Long
    Sequist, Lecia V.
    Tan, Eng-Huat
    Geater, Sarayut L.
    Orlov, Sergey
    Zhang, Li
    Lee, Ki Hyeong
    Tsai, Chun-Ming
    Kato, Terufumi
    Barrios, Carlos H.
    Schuler, Martin
    Hirsh, Vera
    Yamamoto, Nobuyuki
    O'Byrne, Kenneth
    Boyer, Michael
    Mok, Tony
    Peil, Barbara
    Marten, Angela
    Yang, James Chih-Hsin
    Paz-Ares, Luis
    Park, Keunchil
    CLINICAL LUNG CANCER, 2018, 19 (04) : E465 - E479
  • [30] ACTIVITY OF AFATINIB IN UNCOMMON EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS IN LUX-LUNG 3, A PHASE III TRIAL OF AFATINIB OR CISPLATIN/PEMETREXED IN EGFR MUTATION-POSITIVE LUNG CANCER
    Yang, J. C.
    Schuler, M.
    Yamamoto, N.
    O'Byrne, K. J.
    Hirsh, V.
    Mok, T. S. K.
    Massey, D.
    Zazulina, V.
    Shahidi, M.
    Sequist, L. V.
    ANNALS OF ONCOLOGY, 2012, 23 : 410 - 411
12345